Foghorn Therapeutics reported a quarterly loss of $0.10 per share, better than the Zacks Consensus Estimate of a $0.23 loss. The loss also improved versus the prior-year period (from $0.28 per share). Overall, the results represent a modest EPS beat driven by reduced losses.
Foghorn Therapeutics reported a quarterly loss of $0.10 per share, better than the Zacks Consensus Estimate of a $0.23 loss. The loss also improved versus the prior-year period (from $0.28 per share). Overall, the results represent a modest EPS beat driven by reduced losses.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
